Differential susceptibility of retroviruses to nucleoside analogues

Antiviral Chemistry and Chemotherapy

Volumn 12, Issue 2, 2001, Pages 91-97

  Rosenblum, L L ^a   Patton, G ^a   Grigg, A R ^a   Frater, A J ^a   Cain, D ^a   Erlwein, O ^a   Hill, C L ^a   Clarke, J R ^a   McClure, M O ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Abacavir; HFV; SFV 1; SFV 6; SRV 1; SRV 2

Indexed keywords

ABACAVIR; DIDANOSINE; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ANTIBIOTIC SENSITIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; DRUG EFFICACY; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LENTIVIRINAE; MURINE LEUKEMIA VIRUS; NONHUMAN; ONCOVIRINAE; PRIORITY JOURNAL; RETROVIRUS; REVERSE TRANSCRIPTION; SPUMA VIRUS;

EID: 0034869045     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020101200202     Document Type: Article

References (54)

1. In vitro behaviour and structural characteristics of human medulloblastoma in long-term cell cultures
2. Intracellular phosphorylation interactions between nucleoside analogs
3. RNA-dependent DNA polymerase in virions of RNA tumor viruses
4. A comparative study of higher primate foamy viruses, including a new virus from a gorilla
5. High level resistance to (-) enactiomeric 2′-deoxy-3-thiacytidine (3TC) in vitro is due to one amino acid substitution in the catalytic site of HIV-1 reverse transcriptase
6. Broad spectrum antiretroviral activity of 2, 3-dideoxynucleosides
7. Mink lung cells: A non-primate cell line highly susceptible for varicella-zoster virus
8. Delta: A randomized double-blind controlled trial comprising combinations of zidovudine plus didanosine or zalcitrabine with zidovudine alone in HIV infected individuals
9. A sensitive assay for the quantification of reverse transcriptase activity, based on the use of carrier-bound template and non-radioactive product detection, with special reference to human immunodeficiency virus isolation
10. Morphological and virological investigations on cultured Burkitt tumor lymphoblasts (strain Raji)
11. Unique intracellular activation of the potent antihuman immunodeficiency virus agent 1592U89
12. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial
13. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′,3′-dideoxycytidine
14. HIV-1 drug resistance testing
15. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase
16. The effect of zidovudine on chronic myelopathy associated with HTLV-I
17. Effects of (-)-2′-deoxy-3′-thiacytidine (3TC) 5′-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma
18. Virus isolation and quantification
19. Cellular pharmacology of 2′,3′dideoxy-2′,3′-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus
20. Pharmacological resistance to antiretroviral drugs
21. Retroviridae
22. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients: A randomized controlled comparison with zidovudine monotherapy
23. Intracellular activation of 2′,3′-dideoxyinosine and drug interactions in vitro
24. The bottleneck in AZT activation
25. A continuous tumor-cell line from a human lung carcinoma with properties of type II alveolar epithelia cells
26. Transformation and oncogenesis: Retroviruses
27. Polyoma transformation of hampster cell clones - An investigation of genetic factors affecting cell competence
28. A colorimetric reverse transcriptase (RT) assay optimized for Moloney murine leukemia virus, and its use for characterization of RTs of unknown identity
29. Effect of 3′-deoxythymidin-2′-ene (D4T) on nucleoside metabolism on H9 cells
30. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLVIII/LAV) by 2′,3′-dideoxynucleosides
31. 3′-Azido-3′-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro
32. A virus-induced rhabdomyosarcoma of mice
33. Antigenic relationships of human foamy virus to the simian foamy viruses
34. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds
35. In vitro activity of inhibitors of late stages of the replication of HIV in chronically infected macrophages
36. Detection, isolation, and continuous production of cytopathic retrovirus (HTLV-III) from patients with AIDS and pre-AIDS
37. Simian type D retroviruses
38. Non-lentiviral primate retroviruses
39. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir phase 2 clinical team
40. Restricted expression of human T-cell leukemia-lymphoma virus (HTLV) in transformed human umbilical cord blood lymphocytes
41. Inhibition of the in vitro infectivity and cytopathic effect of human foamy virus by dideoxynucleosides
42. Mutations in retroviral genes associated with drug resistance: 1999-2000 update
43. Long terminal repeat U3 length polymorphism of human foamy virus
44. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC)
45. High-dose zidovudine induction in HTLV-I associated myelopathy: Safety and possible efficacy
46. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients
47. 3′-Azido-3′-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase
48. Pathogenesis and treatment of HTLV-I associated myelopathy
49. Antiviral effects of 3′-azido-3′-deoxythymidine (AZT), 2′,3′-dideoxycytidine (ddC), and 2′,3′-dideoxyadenosine (ddA) against simian immunodeficiency syndrome-associated type D retrovirus (SAIDS-D/WA) in vitro
50. Toxicity and efficacy of 2′,3′-dideoxycytidine in clinical trials of pigtail macaques infected with simian retrovirus type 2
51. In vitro screening for antiretroviral agents against simian immunodeficiency virus (SIV)
52. The impact of antiviral therapy on HIV disease
53. Analysis of the role of the bel and bet open reading frames of human foamy virus by using a new quantitative assay
54. Evidence that the human foamy virus genome is DNA